Seeking Alpha
12 Jun 2026, 07:46 UTC · 14w ago
Verdict
Headline takes no side. We score ABT +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Abbott Laboratories has raised its FY26 guidance for both sales and earnings per share (EPS).
More positive than 92% of claims this week
Abbott is currently trading at a 17.1% P/E and 35.1% sales multiple discount relative to its peers.
So whatSignificant structural undervaluation suggests a potential for a valuation rerating if fundamentals remain strong.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 77% of claims this week
The company is pursuing growth through the acquisition of Exact Sciences and global expansion of its continuous glucose monitoring (CGM) business.
More positive than 63% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+15.9%
Price agrees with the score
$103.93 vs $89.65 close before publication (Jun 11) · not market-adjusted
ABT chart →
